Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc reports a strong positive outlook driven by significant revenue growth anticipated from its Signatera minimal residual disease (MRD) testing, with Q3 reflecting a record increase of 21,500 tests quarter-over-quarter and a remarkable 54% year-over-year growth. The company has indicated potential for expanding reimbursement coverage across various cancer types, which is expected to enhance average selling prices (ASP), gross margins, and operating cash flow. Additionally, Natera has revised its 2025 revenue guidance upward by $160 million, following a robust revenue beat of approximately $80 million in Q3, reinforcing confidence in its growth trajectory.

Bears say

Natera faces a negative outlook primarily due to anticipated margin erosion stemming from reduced in-network pricing, as more commercial payors are expected to join the market and the total addressable market expands to include average risk patients. Compression of average selling prices (ASPs) for its Panorama product is also a significant concern, which could further impact profitability. Additionally, ethical concerns surrounding the use of its patented technology and potential reluctance from patients to utilize genetic tests could hinder Natera's growth prospects in the competitive diagnostics landscape.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $225.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $225.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.